Announcements
-
The inaugural issue is now live!
-
RFS Awards in Science Winner
Mary Ann Liebert, Inc., in partnership with the Rosalind Franklin Society launched a prestigious annual award to recognize outstanding published peer-reviewed research by women and underrepresented minorities in science in each of the publisher’s peer-reviewed journals. The RFS Awards in Science for Psychedelic Medicine has selected Jamie Peters, PhD, MBA who co-authored Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.
Aims & Scope
Psychedelic Medicine is the only peer-reviewed, evidence-based resource solely focused on this rapidly expanding area of research. As psychedelic substances move into the mainstream with a growing number of clinical research programs, increasing industry investment, and accelerating legalization/decriminalization measures – Psychedelic Medicine is the central authority with timely coverage on every aspect of psychedelic medicine.
Psychedelic Medicine provides rapid, fair peer-review, and welcomes original research papers including basic science, clinical, and translational research, as well as medical applications.
Psychedelic Medicine coverage includes:
- Serotonin and serotonin receptors, signaling, functional selectivity, and ligand bias
- Tryptamines (e.g. LSD, psilocybin, psilocin, DMT, 5-MeO-DMT)
- Lysergamides (e.g. LSD)
- Addiction
- Animal models
- Drug discovery
- Effects on mental disorders
- fMRI
- Entactogens
- Neuroplasticity
- Palliative care
- Phenethylamines (e.g. mescaline, DOI)
- Psychiatry
- Psychoactive substances (e.g. ibogaine)
- Psychopharmacology
- Psychotherapy
- And more
Psychedelic Medicine is under the editorial leadership of Co-Editors-in-Chief: Peter Hendricks, PhD Professor and Director of Research, Department of Health Behavior, School of Public Health, University of Alabama at Birmingham and Charles Nichols, PhD, Professor of Pharmacology, Louisiana State University Health Sciences Center. View the entire editorial board.
Audience: Pharmacologists and psychopharmacologists, toxicologists, biochemists, neurologists, psychiatrists, as well as addiction specialists, and regulators and policymakers.
